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ABSTRACT
Synthetic biology has significantly advanced the
design of synthetic control devices, gene circuits
and networks that can reprogram mammalian cells
in a trigger-inducible manner. Prokaryotic helix-
turn-helix motifs have become the standard
resource to design synthetic mammalian transcrip-
tion factors that tune chimeric promoters in a small
molecule-responsive manner. We have identified a
family of Actinomycetes transcriptional repressor
proteins showing a tandem TetR-family signature
and have used a synthetic biology-inspired
approach to reveal the potential control dynamics
of these bi-partite regulators. Daisy-chain
assembly of well-characterized prokaryotic repres-
sor proteins such as TetR, ScbR, TtgR or VanR and
fusion to either the Herpes simplex transactivation
domain VP16 or the Krueppel-associated box
domain (KRAB) of the human kox-1 gene resulted
in synthetic bi- and even tri-partite mammalian tran-
scription factors that could reversibly program their
individual chimeric or hybrid promoters for trigger-
adjustable transgene expression using tetracycline
(TET), c-butyrolactones, phloretin and vanillic acid.
Detailed characterization of the bi-partite ScbR-
TetR-VP16 (ST-TA) transcription factor revealed
independent control of TET- and c-butyrolactone-
responsive promoters at high and double-pole
double-throw (DPDT) relay switch qualities at low
intracellular concentrations. Similar to electromag-
netically operated mechanical DPDT relay switches
that control two electric circuits by a fully isolated
low-power signal, TET programs ST-TA to progres-
sively switch from TetR-specific promoter-driven
expression of transgene one to ScbR-specific
promoter-driven transcription of transgene two
while ST-TA flips back to exclusive transgene 1 ex-
pression in the absence of the trigger antibiotic. We
suggest that natural repressors and activators with
tandem TetR-family signatures may also provide in-
dependent as well as DPDT-mediated control of two
sets of transgenes in bacteria, and that their syn-
thetic transcription-factor analogs may enable the
design of compact therapeutic gene circuits for
gene and cell-based therapies.
INTRODUCTION
During the past 20 years, bioengineers have constructed
an impressive portfolio of basic mammalian transcription-
control devices (1–3) that are based on the same design
principles as the inaugural gene switch known as the tetra-
cycline- (TET) responsive expression or TET system (4).
The TET system’s blueprint consists of a bacterial repres-
sor protein (TetR), managing TET resistance in
Escherichia coli, that is fused to the Herpes simplex trans-
activation domain VP16 to form a synthetic TET-depend-
ent transactivator (tTA; TetR-VP16) or to the Krueppel-
associated box (KRAB) domain of the human kox-1 gene
to form a TET-dependent transsilencer (tTS; TetR-KRAB
(5). The tTS binds to TetR-speciﬁc operator sites (tetO)
downstream of a simian virus 40 promoter (PSV40) and
represses PSV40-driven transgene expression in a TET-re-
sponsive manner (5). Likewise, tTA binds to a chimeric
TET-responsive promoter (PhCMV*1), assembled by
placing a heptameric tetO7 operator module immediately
upstream of a minimal version of the human cytomegalo-
virus immediate early promoter (PhCMVmin), which
controls transgene expression in a TET-responsive
manner (4). TET system design variants using identical
VP16/PhCMVmin modules, but repressor/operator
componentry of different bacteria are responsive to
erythromycin (6), tryptophan (7), uric acid (8) as well as
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g-butyrolactone (9,10), phloretin (11) and vanillic
acid (3,12). All of these mammalian transgene-control
systems are compatible with each other and can be used
for independent control of different transgenes (6) or func-
tionally interconnected to provide higher-order switching
behavior such as regulatory cascades (13–15), epigenetic
toggle switches (16) hysteretic circuits (17), band-pass
ﬁlters (18,19), tunable oscillators (20) and single-cell bio-
computers (2). Trigger-controlled transcription-tuning
devices have also been successfully used for the design of
drug circuits (21), and there are increasing efforts across
the synthetic biology community to develop control
devices for clinical applications (22–27).
TetR family members are characterized by a conserved
N-terminal DNA-binding region (28) forming the DNA-
binding helix-turn-helix (HTH) DNA-binding motif that
is found in most prokaryotic transcription factors (28,29)
and a non-conserved C-terminal domain (28) that is
responsible for dimerization and ligand recognition (28).
TetR has been successfully mutated to expand its dynamic
range and functional space (30–34). For example, a few
point mutations can reverse TetR’s DNA-binding
function so that the repressor binds instead of dissociates
in the presence of the trigger molecule (30,32,35), and
engineering of TetR enables the repressor to recognize
new trigger molecules (31) or operator sites (36).
However, undesired heterodimerization of functionally
diversiﬁed TetR variants has limited their use for inde-
pendent control of different transgenes (34). To prevent
heterodimerization, either the dimerization domain could
be modiﬁed (37) or monomeric single-chained TetR
variants have been constructed by assembling two TetR
subunits head-to-tail via a ﬂexible hinge region (33,34).
Bipartite DNA-binding domains have also been
identiﬁed in nature. For example, several mammalian dif-
ferentiation factors such as Oct-1 and Oct-2 contain POU
domains with two independent DNA-binding motifs
(29,38), members of the Pax and Prd family of develop-
mental transcription factors harbor two-part DNA motifs
and the Tc1/mariner superfamily of transposable elements
include split DNA-binding modules (39).
Despite their recurrent emergence across different
kingdoms suggesting that bipartite DNA-binding
proteins play an important role in living systems, most
of their regulation dynamics remain elusive. Using a syn-
thetic biology-inspired reverse engineering approach, we
designed artiﬁcial TetR and GntR family-derived bipartite
and tripartite transcription factors, which, besides
showing independent regulation of different sets of trans-
genes, exhibited control dynamics reminiscent of double-
pole double-throw (DPDT) relay switches. DPDT relay
switches are electromagnetically operated mechanical
switches that control one or several electric circuits by a
fully isolated ‘low-power’ signal. DPDT relays were
extensively used in telephone exchanges and early com-
puters to perform logic operations. Likewise, their
genetic counterparts may enable an organism to switch
between global metabolic networks and could provide
logic operations that interface prosthetic networks with
endogenous metabolic circuits in future gene- and cell-
based therapies.
MATERIALS AND METHODS
Plasmid design
Table 1 lists all plasmids used in this study and provides
detailed information about their construction. All relevant
genetic components have been conﬁrmed by sequencing
(Microsynth, Balgach, Switzerland).
Bioinformatics
Protein sequence homology was analyzed using BLASTP
(http://blast.ncbi.nlm.nih.gov). Structure homology and
multiple sequence alignments were scored using the
CLUSTAL W program (43) running on the ExPASY
web server (http://swissmodel.expasy.org/). Batch second-
ary structure alignments were performed using the Jpred 3
secondary structure prediction server (44) (http://www.
compbio.dundee.ac.uk/jpred).
Cell culture
Human bone marrow stromal cells (hMSCs) immortalized
by expression of the human telomerase (hTERT; hMSC-
TERT) catalytic subunit (45), as well as human embryonic
kidney cells (HEK-293T, ATCC: CRL-11268), and its de-
rivatives were cultivated in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% fetal calf
serum (FCS) (FCS; cat. no. 201F10, lot no. PE01026P,
Bioconcept, Allschwil, Switzerland) and 1% (v/v) penicil-
lin/streptomycin solution (Biowest, Nuaille´, France, cat.
no. L0022-100, lot no. S09965L0022). All cells were
cultivated at 37C in a humidiﬁed atmosphere containing
5% CO2. Viable cell numbers were determined using a
Casy Cell Counter and Analyser Model TT (Roche
Diagnostics GmbH, Basel, Switzerland).
Transfections
hMSC-TERT were transfected using an optimized
polyethyleneimine (PEI)-based protocol (17). In brief, a
transfection solution containing 1.5 ml of PEI (PEI ‘Max’,
stock solution 1mg/ml in ddH2O; Polysciences, Eppelheim,
Germany; cat. no. 24765-2) and 0.5mg of plasmid DNA
mixtures was incubated for 15min at 22C before it was
added dropwise to 1 105 hMSC-TERT seeded per well of
a 24-well plate 24 h before transfection. HEK-293T were
transfected with 0.5 mg of DNA using an optimized calcium
phosphate-based protocol. In brief, in each well of a 48-well
plate, 25 000 HEK-293T cells were transfected using a
DNA-Ca2PO4 precipitate that was prepared by mixing
12.5 ml of the plasmid-containing 0.5M CaCl2 solution
with 12.5ml of a 2 HEPES-buffered saline (HBS)
solution [50mM HEPES, 280mM NaCl, 1.5mM
Na2HPO4 (pH 7.1)] for 1min at 22
C. After 3 h, the cells
were washed once with phosphate-buffered saline (PBS)
(Dulbecco’s phosphate-buffered saline; Invitrogen, Basel,
Switzerland, cat. no. 21600-0069) and cultivated for 48 h in
250 ml of FCS-supplemented DMEM containing different
concentrations or combinations of control compounds
before reporter protein levels [human placental secreted
alkaline phosphatase (SEAP), Gaussia luciferase (GLuc)]
were proﬁled in the culture supernatant. For analysis of the
DPDT relay switch expression reversibility, transfected
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cells were cultivated for 24 h in the presence of TET. Then,
the culture medium was collected, the cells were washed
twice with 500 ml of fresh medium and grown for another
24 h in fresh medium in the presence or absence of TET
before SEAP and GLuc levels were proﬁled in the culture
supernatant.
Stable cell line
The stable HEK-293T-derived cell line HEK-293ST-TA,
transgenic for low constitutive PhCMVmin-driven ScbR-
TetR-VP16 (ST-TA) expression, was constructed by co-
transfection of 800 ng of pAS1 (PhCMVmin-ST-TA-pA)
and 100 ng of pZeoSV2(+). After 14 days of selection in
DMEM containing 100 mg/ml (w/v) zeocin (Invivogen,
San Diego, CA, USA, cat. no. ant-zn-1), resistant cell
clones were expanded and screened for functional ST-
TA expression by transient co-transfection with
pWW124 and pDA43 (ratio 1:1) followed by quantiﬁca-
tion of SEAP activity in the presence of different concen-
trations of TET. The best-in-class HEK-293ST-TA cell line
was chosen for further experiments.
Quantiﬁcation of reporter gene expression
SEAP was quantiﬁed as described before (40) using an
EnVision 2104 multilabel reader (absorbance 405 nm;
PerkinElmer, Waltham, MA, USA). GLuc was quantiﬁed
using the BioLux GLuc assay (E3300S, New England
Biolabs) and the EnVision 2104 multilabel reader
(maximum emission 482 nm). Reporter proteins were typ-
ically proﬁled 48 h after transfection. Each error bar is the
mean±standard deviation of the mean of SEAP or GLuc
activity measured in triplicate from a representative ex-
periment repeated three times.
Control compounds
TET (Sigma-Aldrich, cat. no. T7660), stock solution 1mg/
ml in ddH2O (41); SCB1 [2-(1
0-hydroxy-6-methylheptyl)-3-
(hydroxymethyl)-butanolide], stock solution 1mg/ml in
dimethyl sulfoxide (9); Phloretin (Sigma-Aldrich, St.
Louis, cat. no. P7912), stock solution 25mM in dimethyl
sulfoxide (11); Vanillic acid (ABCR, Karlsruhe, Germany,
cat. no. AB177480), stock solution 200mM in ethanol (12).
Western blot analysis
Cells were grown in a 10 cm culture dish, detached 72 h
after transfection, washed once in phosphate-buffered
saline and lysed on ice in 200 ml of lysis buffer [0.14M
NaCl, 0.1M HEPES (pH 7.4) 1.5% (w/v) Triton X-100
and protease inhibitor cocktail (Sigma-Aldrich; cat. no.
P8340)] by sonication for 30 s (Sonopuls mini20, Bandelin
electronic GmbH). The cell lysate was centrifuged twice at
14 000 g for 20min at 4C to remove cell debris, and the
protein content was quantiﬁed using a Bradford assay
(BIO-RAD, Hercules, CA, cat. no. 500-0002). In all,
10 mg of crude protein extract was mixed with 5 ml of gel
loading buffer [10ml; 10% SDS; 1.25ml 0.5M Tris–HCl
(pH 6.8), 3ml glycerol, 0.2ml 0.5% (w/v) bromophenol
blue, 5.55ml ddH2O]. The proteins were resolved on a
12% SDS–PAGE and electroblotted (Trans-Blot SD,
Bio-Rad, Reinach, Switzerland) onto a polyvinylidene
diﬂuoride (PVDF) membrane (Immobilon-P, Millipore,
Billerica, MA, USA). The membrane was blocked with 5%
(w/v) bovine serum albumin (Sigma-Aldrich, cat. no.
A9418) diluted in Tris-buffered saline [20mM Tris,
150mM NaCl (pH 7.6), 0.1% Tween-20] for 1 h at 22C
and incubated over night at 4C with a mouse monoclonal
anti-TetR antibody (MoBiTec, Go¨ttingen, Germany; cat.
no. TET02, lot no. MO2204010). The membrane was then
washed three times in Tris-buffered saline and incubated
for 1 h with a horseradish peroxidase-coupled sheep anti-
mouse immunoglobulin G (GE Healthcare, Switzerland;
cat. no. NA931V, lot no. 399402). Likewise, for loading
control, the membrane was probed with a rabbit polyclonal
anti-a-actin antibody (Sigma, Saint Louis, USA; cat. no
A2066, lot no.03044844) and a horseradish peroxidase-
coupled sheep anti-rabbit immunoglobulin G (AbD
Serotec, Oxford, UK, cat. no. STAR54). ECL-Plus
western blot detection reagents (Amersham, Piscataway,
NJ, USA; cat. no. RPN2232) were used for chemilumines-
cence-based signal detection using a Chemilux CCD
camera (ImageQuantTM, LAS 400 mini, GE Healthcare,
Switzerland).
RESULTS
Mce3R belongs to a new family of Actinomycetes
repressors
Mycobacterium tuberculosis harbors four homologous mce
operons with similar genetic arrangement (46,47) that
have been suggested to manage the pathogen’s lipid
import and metabolism (48,49). The mce3 gene cluster is
negatively controlled by Mce3R (Rv1963c), a TetR family
transcriptional regulator that contains a unique double
TetR-family signature consisting of two DNA-binding
HTH motifs (50,51). The weak homology between the
tandem TetR units suggests that Mce3R might have
resulted from a fusion of two diverse TetR repressors
rather than representing an evolutionary snapshot of a
standard gene duplication-diversiﬁcation process. The
function, control characteristics and tuning dynamics of
this tandem TetR–TetR fusion motif as well as the
question whether Mce3R could possibly be responsive to
two distinct trigger molecules and address different target
genes for differential control of metabolic activities remain
elusive. Multiple alignment analysis of Mce3R’s secondary
structure revealed that 204 other putative Actinomycetes
repressor proteins share such a double TetR-family signa-
ture, suggesting that Mce3R is a prototype of a larger
family of repressor fusion proteins with common control
characteristics (Figure 1A).
Design of synthetic bipartite mammalian transactivators
Using Mce3R’s unique architecture as a blueprint, we
have used a synthetic biology-inspired reverse engineering
approach to design tandem TetR-family repressor-derived
fusion proteins with dual input–output control capacity.
Therefore, two validated TetR-family repressor proteins
such as the TET-responsive repressor TetR [T; (4)] and
the g-butyrolactone-adjustable repressor ScbR [S; (9)]
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were fused and linked to a Herpes simplex virus-derived
VP16 transactivation domain to form chimeric dual-input
transcription factors that could individually bind and
program transcription of their speciﬁc pairs of target pro-
moters such as the TET [PhCMV*1; (4)] or SCB1 [PSPA;
(9)] -responsive promoters (Figure 1B and C). Indeed, in
human cells, the synthetic dual TetR-family transactivator
ST-TA (pMX1) was able to induce its cognate target pro-
moters PSPA and PhCMV*1 (PSPA-SEAP, pWW124;
PhCMV*1-SEAP, pMF111) and provide similar SEAP
production characteristics compared with the individual
transactivators ScbR-VP16 (SCA; pWW122) and TetR-
VP16 (tTA; pSAM200) (Figure 2A). Also, ST-TA
retained the control capacity of their isogenic individual
counterparts and remained responsive to TET and the
butyrolactone SCB1 (Figure 2B), which conﬁrms that,
even in a scaffold conﬁguration, TetR family repressor
proteins individually act as fully functional DNA-binding
domains, and that they can share a common transactiva-
tion domain to trigger expression of different transgenes.
Conservation profile
A
α1      α2    α3       α4            α5          α6            α7                α8                           α9            α1  α2  α3         α4             α5         α6           α7               α8              α9Predicted α−helix 
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Figure 1. Tandem TetR-family scheme. (A) Multiple alignment analysis of Mce3R’s predicted alpha helical secondary structure reveals a double
TetR-family signature consisting of typical DNA-binding HTH and ligand-binding domain (LBD) domains that is present in over 200 other putative
Actinomycetes repressor proteins. Therefore, Mce3R may be a prototype of a larger family of natural repressor fusion proteins sharing speciﬁc
transcription-control characteristics. (B) Synthetic bipartite TetR-family repressor-derived mammalian transcription factors with dual input–output
control capacity. Bipartite TetR-family repressor-derived mammalian transactivator variants assembled by fusing the TET- and g-butyrolactone-
dependent repressor proteins (TetR, ScbR) to the Herpex simplex virus-derived transactivation domain (VP16). Corresponding target promoters
contain speciﬁc operator sites (tetO7, OPapR1) immediately 5
0 of a minimal version of the human cytomegalovirus immediate early promoter
(PhCMVmin) and control expression of the human placental SEAP gene. (C) Interaction diagram of individual and tandem transactivator components
with corresponding expression units.
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Figure 2. Performance of bipartite TetR-family transcription factors. (A) Regulation characteristics of the ScbR-TetR-VP16 (ST-TA) and TetR-
ScbR-VP16 (TS-TA) transactivators. HEK-293T cells were co-transfected with ST-TA (pMX1) or TS-TA (pMX10) and either PhCMV*1- (pMF111)
or PSPA- (pWW124) driven SEAP expression vectors. Isogenic cultures expressing tTA (pSAM200) or SCA (pWW122) instead of ST-TA (pMX1)
were used as controls. Cells were grown for 48 h in the presence or absence of the trigger molecules TET or the g-butyrolactone (SCB1) before the
SEAP levels in the culture supernatant were quantiﬁed. (B) TET- and g-butyrolactone- (SCB1) adjustable ST-TA-driven transgene expression. HEK-
293T cells were transfected with either pMX1/pWW124 or pMX1/pMF111 and cultivated for 48 h in the presence of different concentrations of TET
or SCB1 before SEAP was scored in the culture supernatant. HEK-293T transfected with either tTA (pSAM200) or SCA (pWW122) instead of
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(continued)
Thus, the Mce3R-mimetic ST-TA pioneers a new class of
composite control proteins that could adjust their individ-
ual target promoters in response to speciﬁc molecular
inputs. As the relative position of TetR family members
within the scaffold transactivator may have an effect on
its control capacity, we have reversed the position of
ScbR and TetR, which resulted in TS-TA (TetR-ScbR-
VP16; pMX10) (Figure 1B). However, TS-TA could only
marginally trigger SEAP expression from its individual
target promoters PhCMV*1 (pMF111) and PSPA
(pWW124) (Figure 2A).
Design of synthetic tandem transsilencers
To design tandem transcription factors with ON-type
switch characteristics, we replaced the VP16 transactiva-
tion domains of ST-TA and TS-TA with the KRAB
domain of the human kox-1 gene, which resulted in the
transsilencer (TS) variants ST-TS (ScbR-TetR-KRAB;
pMX63) and TS-TS (TetR-ScbR-KRAB; pMX65)
(Figure 2C). In the absence of any trigger compounds,
ST-TS bound to speciﬁc operator modules (OpapRI,
tetO2) and silenced the corresponding chimeric target pro-
moters PSPS (PSV40-OPapRI-SEAP-pA; pMX65) and
PtTSON2 (PSV40-tetO2-SEAP-pA; pMX67). In the
presence of either SCB1 or TET, ST-TS was released
from PSPS and PtTSON2, and constitutive SEAP expres-
sion was restored (Figure 2D). TS-TS failed to control
both promoters, suggesting that not all dual-TetR archi-
tectures are fully functional (data not shown).
Transactivator scaffolding as a general design concept
The principle of designing multi-input/output control
devices by assembling different TetR-familiy members in
a single protein scaffold could be validated by the con-
struction of PT-TA (TtgR-TetR-VP16; pMX29) and TP-
TA (TetR-TtgR-VP16; pFS1), two chimeric transcription
factors combining the phloretin [P; (9)] and the TET [T;
(4)] -dependent repressors with a single C-terminal VP16
transactivation domain (Figure 3A). Akin to ST-TA, both
PT-TA and TP-TA were able to retain the interference-
free control of individual PTtgR1- (phloretin-responsive
promoter) and PhCMV*1-driven transgene expression in
response to the trigger molecules phloretin and TET, re-
spectively (Figure 3B). This suggests that the design of
functional transactivators with a double TetR-family sig-
nature could represent a universal principle. By way of
preliminary example, we also daisy chained three inde-
pendent TetR-family repressors (TetR, ScbR and TtgR)
to generate the three-in-one transactivator PTS-TA
(TtgR-TetR-ScbR-VP16; pMX27) (Figure 3A) that could
control all individual target promoters (PhCMV*1, PSPA,
PTtgR1) in response to the speciﬁc trigger molecules TET,
SCB1 and phloretin, respectively (Figure 3C).
Transactivator scaffolding is not limited to TetR-family
members
To evaluate whether this scaffold standard could be
extended beyond the TetR repressor family, we also
included the GntR-type transcriptional repressor VanR
that controls lignin metabolism of Caulobacter crescentus
in response to vanillic acid (11,52). In contrast to the TetR
family whose DNA-binding motif contains two alpha-
helical structures, VanR’s binding capacity is based on a
winged HTH motif that contains three alpha helices (53).
We have constructed two VanR-containing dual-control
devices by sequentially permutating VanR and TetR:
TV-TA (TetR-VanR-VP16; pMX6) and VT-TA (VanR-
TetR-VP16; pMX25) (Figure 4A). When co-transfecting
either of the dual-control transactivator variants with
either VanR- (P1VanO2; pMG252) or TetR (PhCMV*1;
pMF111)-speciﬁc reporter constructs into human cells,
only VT-TA was able to independently transactivate
(Figure 4B) and control (Figure 4C) PhCMV*1 (pMF111)
as well as P1VanO2 (pMG252)-driven transgene expression
in response to TET and vanillic acid, respectively. This
demonstrates that the concept of fusing prokaryotic re-
pressor proteins of different families to achieve differential
small molecule-responsive transgene expression in mam-
malian cells works in principle, but that there remain some
unknown design rules that may limit functionality and
predictability.
Bipartite transactivators show independent two-transgene
control characteristics at high intracellular concentrations
With ST-TA’s trigger-controlled ﬁne-tuning of its individ-
ual target promoters PSPA and PhCMV*1 established
(Figure 2B), we also assessed whether this bipartite
transactivator could differentially adjust two distinct
transgenes in response to independent molecular inputs.
We have therefore co-transfected HEK-293T cells with
high amounts of the ST-TA-encoding plasmid (pMX1)
relative to PSPA-driven SEAP (pWW124) and PhCMV*1-
driven GLuc (pDA43) expression vectors (ratio 20:1:1). At
high intracellular ST-TA concentrations, the composite
transactivator was able to simultaneously control its
speciﬁc target promoters and independently ﬁne-tune
SEAP and GLuc expression in a SCB1 and TET-respon-
sive manner (Figure 5A). As neither SCB1 affected GLuc
expression nor TET inﬂuenced SEAP expression, ST-TA
manages independent interference-free two-input/two-
output transcription ﬁne tuning in a most compact
format.
Figure 2. Continued
ST-TA (pMX1) were used as controls. (C) Synthetic bipartite TetR-family repressor-derived mammalian transsilencers. Tandem TetR-family repres-
sor-derived mammalian transsilencer variants assembled by fusing the TET- and g-butyrolactone-dependent repressor proteins (TetR, ScbR) to the
KRAB domain of the human kox-1 gene. Corresponding target promoters contain speciﬁc operator sites (tetO2, OPapR1) immediately 3
0 of the
constitutive simian virus 40 promoter (PSV40) and control expression of the human placental SEAP. (D) Performance of the ScbR-TetR-KRAB (ST-
TS) and TetR-ScbR-KRAB (TS-TS) transsilencers. HEK-293T cells were co-transfected with ST-TS (pMX63) or TS-TS (pMX64) and either PSPS-
(pMX65) or PtTSON2- (pMX67) driven SEAP expression vectors and grown for 48 h in the presence (1mg/ml) or absence of the trigger molecules
TET or the g-butyrolactone (SCB1) before SEAP levels were scored in the culture supernatant. Isogenic cultures transfected with either pMX65 or
pMX67, but no transsilencer-encoding plasmids were used as controls.
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Figure 3. Characterization of synthetic bi- and tri-partite TetR-family transactivators. (A) Bi- and tri-partite TetR-family repressor-derived mam-
malian transactivator variants assembled by fusing the TET-, phloretin- and g-butyrolactone-dependent repressor proteins (TetR, TtgR, ScbR) to the
Herpex simplex virus-derived transactivation domain (VP16). All multi-partite transactivator-encoding expression units are driven by the constitutive
simian virus 40 promoter (PSV40) and contain a polyadenylation signal (pA). Corresponding target promoters contain speciﬁc operator sites (tetO7,
OTtgR, OPapR1) immediately 5
0 of a minimal version of the human cytomegalovirus immediate early promoter (PhCMVmin) and control expression of
the human placental SEAP. (B) Regulation performance of the TtgR-TetR-VP16 (PT-TA) and TetR-TtgR-VP16 (TP-TA) transactivators. HEK-
293T cells were co-transfected with PT-TA (pMX29) or TP-TA (pFS1) and either PhCMV*1- (pMF111) or PTtgR1- (pMG10) driven SEAP expression
vectors. Isogenic cultures expressing tTA (pSAM200) or TtgA1 (pMG11) instead of PT-TA (pMX29) or TP-TA (pFS1) were used as controls. Cells
were grown for 48 h in the presence or absence of the trigger molecules TET (1mg/ml) or phloretin (PLT, 0.2 mg/ml) before SEAP levels were scored
in the culture supernatant. (C) Regulation performance of the tripartite TtgR-TetR-ScbR-VP16 transactivator (PTS-TA). HEK-293T cells were co-
transfected with PTS-TA (pMX27) and either PhCMV*1- (pMF111), PSPA- (pWW124) or PTtgR1- (pMG10) driven SEAP expression vectors. Isogenic
cultures expressing tTA (pSAM200), SCA (pWW122) or TtgA1 (pMG11) instead of PTS-TA (pMX27) were used as controls. Cells were grown for
48 h in the presence or absence of the trigger molecules TET (1 mg/ml), g-butyrolactone (SCB1, 1mg/ml) or the phloretin (PLT, 0.2 mg/ml) before
SEAP levels were proﬁled in the culture supernatant.
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Figure 4. Bi-partite TetR/GntR-family repressor-derived mammalian transactivators with dual input–output control capacity. (A) Bi-partite
TetR/GntR-family repressor-derived mammalian transactivator variants assembled by fusing the TET- and vanillic acid-responsive repressor
proteins (TetR, VanR) to the Herpex simplex virus-derived transactivation domain (VP16). The bi-partite transactivator-encoding expression
units are driven by the constitutive simian virus 40 promoter (PSV40) and contain a polyadenylation signal (pA). Corresponding target promoters
contain domain-speciﬁc operator sites VanO2 and tetO7 immediately 5
0 of a minimal version of the human cytomegalovirus immediate early
promoter (PhCMVmin) that controls expression of the human placental SEAP. (B) Regulation performance of the TetR-VanR-VP16 (TV-TA) and
VanR-TetR-VP16 (VT-TA) transactivators. HEK-293T cells were co-transfected with TV-TA (pMX6) or VT-TA (pMX25) and either PhCMV*1-
(pMF111) or P1VanO2- (pMG252) driven SEAP expression vectors. Isogenic cultures expressing tTA (pSAM200) or VanA1 (pMG250) instead of TV-
TA (pMX6) or VT-TA (pMX25) were used as controls. Cells were grown for 48 h before SEAP levels were quantiﬁed in the culture supernatant.
(C) Trigger responsiveness of the VanR-TetR-VP16 (VT-TA) transactivator. HEK-293T cells were co-transfected with VT-TA (pMX25) and either
PhCMV*1- (pMF111) or P1VanO2- (pMG252) driven SEAP expression vectors and grown for 48 h in the presence and absence of the trigger molecules
vanillic acid (VAC, 17 mg/ml) or TET (1 mg/ml) before SEAP levels were scored in the culture supernatant.
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Figure 5. Two-gene control dynamics of the ST-TA transactivator. (A) Independent control of two different transgenes. HEK-293T cells
were co-transfected with the ST-TA-encoding plasmid pMX1, the PSPA-driven SEAP- (pWW124) and PhCMV*1-driven GLuc- (pDA43) ex-
pression vectors at a high transactivator-to-reporter ratio (20:1:1) and grown for 48 h in culture medium containing increasing concentrations of
TET or g-butyrolactone (SCB1) before SEAP and GLuc levels were quantiﬁed in the culture supernatant. (B) DPDT relay switch characteristics.
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(continued)
Composite transactivators show DPDT relay switch
characteristics at low intracellular concentrations
When co-transfecting HEK-293T cells with lower
amounts of ST-TA-encoding plasmid (pMX1) relative to
PSPA-driven SEAP (pWW124) and PhCMV*1-driven GLuc
(pDA43) expression vectors (ratio 1:12:12), ST-TA trig-
gered maximum GLuc levels, whereas SEAP expression
remained low. Following addition of increasing concen-
trations of TET, ST-TA is gradually released from
PhCMV*1, leading to progressive shut down of GLuc ex-
pression and switches to exclusive binding of PSPA, which
then results in dose-dependent induction of SEAP produc-
tion (Figure 5B). This TET-induced switch from GLuc to
SEAP expression was an exclusive characteristic of the bi-
partite ST-TA, as control experiments with individual
transactivators (SCA, tTA) resulted in GLuc shut down
but not in SEAP induction after addition of TET
(Figure 5C). The DPDT relay switch characteristics
could be conﬁrmed in telomerase-immortalized hMSC-
TERT using an identical experimental set-up
(Figure 5D). At lower ST-TA concentration (ratio
1:12:12), the DPDT relay switch is reversible as removal
of TET switches ST-TA back to binding of PhCMV*1,
which results in shut down of SEAP expression and con-
comitant induction of GLuc (Figure 5E and F).
The TET-controlled change over from PhCMV*1 to
PSPA and switch back from PSPA to PhCMV*1 thereby
modulating expression of two different transgenes repre-
sents the genetic version of a DPDT relay switch. DPDT
relays consist of an electromagnet that, on activation by
an electric current (TET), simultaneously switches two
moving plates (two poles; TetR and ScbR of ST-TA)
that may engage either of two different sets of ﬁxed
contacts (PhCMV*1 and PSPA) to switch one contact
from ON-to-OFF (GLuc) and the other one from OFF-
to-ON (SEAP) (the double throw) (Figure 5F). Although
the electric DPDT relay is limited to digital switching, its
genetic counterpart shows additional dimmer switch
quality at intermediate inducer concentrations when
GLuc expression is gradually shut down while SEAP pro-
duction is progressively turned on and vice versa
(Figure 5B and D).
To validate the DPDT relay switching characteristics at
low composite transactivator levels, we produced a stable
ST-TA-transgenic cell line HEK-293TST-TA in which ST-
TA is driven by leaky transcription of the minimal version
of the human cytomegalovirus immediate early promoter
(PhCMVmin; pAS1) (Figure 6A) and therefore expresses
the tandem transactivator at low constitutive levels
(Figure 6B). Co-transfection of HEK-293TST-TA with
pDA43 and pWW124 conﬁrmed the circuit’s DPDT
relay switching capacity (Figure 6C). To explore func-
tional compatibility of the composite transactivator
(ST-TA) and the individual transactivators (tTA, SCA)
in the same cell using a DPDT experimental set-up, we
co-transfected HEK-293TST-TA with the tTA (pSAM200)
and SCA (pWW122) expression vectors as well as with the
DPDT reporter plasmids pDA43 (PhCMV*1-SEAP) and
pWW124 (PSPA-SEAP) and proﬁled reporter protein pro-
duction before and after addition of TET (Figure 6D),
showing that the presence of tTA does not interfere with
ST-TA’s switch from PSPA-GLuc to PhCMV*1-SEAP, as
GLuc levels decrease and SEAP levels increase when the
culture is switched from TET to+TET. Likewise, SCA
NONO OFF OFF
TetracyclinePSPAPhCMV*-1
PSPA
PhCMVmin pWW124pASEAP
ST-TA
Electromagnet
+TET
PhCMVmin pDA43pAGLuc
-TET
PhCMV*-1
F
Figure 5. (continued)
HEK-293T cells were co-transfected with the ST-TA-encoding plasmid pMX1, the PSPA-driven SEAP- (pWW124) and PhCMV*1-driven GLuc- (pDA43)
expression vectors at a low transactivator-to-reporter ratio (1:12:12) and grown for 48h in culture medium containing increasing concentrations of TET
before SEAP and GLuc levels were quantiﬁed in the culture supernatant. (C) HEK-293T cells were co-transfected with the tTA- and SCA- expression
vectors (pSAM200, pWW122) and corresponding reporter plasmids pDA43 (PhCMV*1-GLuc) and pWW124 (PSPA-SEAP) (ratio 1:1:5:5), grown for 48h
in culture medium containing increasing concentrations of TET before expressed SEAP and GLuc levels were quantiﬁed in the culture supernatant. (D)
DPDT relay switch characteristics of hMSC-TERT cells. hMSC-TERT cells were co-transfected with the ST-TA-encoding plasmid pMX1, the PSPA-
driven SEAP- (pWW124) and PhCMV*1-driven GLuc- (pDA43) expression vectors in a low transactivator-to-reporter ratio (1:12:12) and grown for 48h
in culture medium containing increasing concentrations of TET before SEAP and GLuc levels were quantiﬁed in the culture supernatant. (E)
Reversibility of ST-TA-mediated DPDT relay switch characteristics. HEK-293T cells were co-transfected with the ST-TA-encoding plasmid pMX1,
the PSPA-driven SEAP- (pWW124) and PhCMV*1-driven GLuc- (pDA43) expression vectors in a low transactivator-to-reporter ratio (1:12:12) and
grown for 24h in the presence (1mg/ml) or absence of TET and SEAP, and GLuc levels were proﬁled in the culture supernatant. The same cells were
then washed and incubated with fresh medium and grown for another 24h in the presence (TET, 1mg/ml) or absence of TET (TET to no TET), before
SEAP and GLuc levels were proﬁled in the culture supernatant. (F) Schematic of the electric and genetic DPDT relay switch.
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does not interfere with ST-TA’s switch from PSPA-GLuc
to PhCMV*1-SEAP, as GLuc levels decrease and SEAP
levels remain constant when the culture is switched from
TET to +TET (Figure 6D). This is remarkable and
shows that composite and individual transactivators can
in principle operate side-by-side in an interference-free
manner in the same cell.
Design of hybrid promoters for bipartite transactivators
To further study the control behavior of tandem TetR-
family transcription factors such as ST-TA and TS-TA,
we designed hybrid promoter variants that combined one
(PST-TA/TS-TA1; tetO-OPapRI-PhCMVmin; pMX8) or two (PST-
TA/TS-TA2; tetO-tetO-OPapRI-PhCMVmin; pMX9) TetR-
speciﬁc binding sites (tetO) with a single ScbR-speciﬁc
binding site (OPapRI), all separated by two helical turns,
with a minimal version of the human cytomegalovirus im-
mediate early promoter (Figure 7A). Although ST-TA was
able to activate individual (PhCMV*1 and PSPA) (Figure
2A) as well as both hybrid promoter versions (PST-TA/TS-
TA1, PST-TA/TS-TA2) (Figure 7B), TS-TA exclusively
controlled the hybrid promoters (Figures 2A and 7B). As
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Figure 6. (A) ST-TA driven by a minimal version of the human cytomegalovirus immediate early promoter. (B) Western blot-based analysis of
ST-TA expression levels. Lanes left to right: ST-TA (pMX1) transiently transfected into HEK-293T; HEK-293TST-TA stably expressing ST-TA at
low levels; tTA (pSAM200) transiently transfected into HEK-293T; non-transfected HEK-293T cells used as control. (C) HEK-293TST-TA cells
were co-transfected with the PSPA-driven SEAP (pWW124) and PhCMV*1-driven GLuc (pDA43) expression vectors (plasmid ratio 1:1) and grown for
24 h in culture medium containing increasing concentrations of TET before SEAP levels, and GLuc were proﬁled in the culture
supernatant. (D) Compatibility of the DPDT relay with tTA and SCA. HEK-293TST-TA cells were co-transfected with the PSPA-driven SEAP
(pWW124) and PhCMV*1-driven GLuc (pDA43) expression plasmids (ratio 13:20:20), and either the tTA (pSAM200) or SCA (pWW122) expression
vectors, and grown for 48 h in the presence or absence of 1 mg/ml TET before SEAP and GLuc levels were proﬁled in the culture supernatant.
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Figure 7. Regulation characteristics of ST-TA and TS-TA-speciﬁc hybrid promoters. (A) Schematic of ST-TA- and TS-TA-speciﬁc promoter
variants combining one (PST-TA/TS-TA1) or two (PST-TA/TS-TA2) tetOs (orange) with a single ScbR-speciﬁc binding site (OPapRI, blue), all separated
by two helical turns, with a minimal version of the human cytomegalovirus immediate early promoter. (B) Maximum ST-TA- and TS-TA-dependent
induction of the hybrid promoters in the absence of any control molecules. HEK-293T cells were co-transfected with either the SCA- (pWW122),
tTA- (pSAM200), ST-TA- (pMX1) or TS-TA- (pMX10) encoding plasmids in combination with either PST-TA/TS-TA1 (pMX8, gray) or PST-TA/TS-TA2
(pMX9, black) and cultivated for 48 h before SEAP levels were quantiﬁed in the culture supernatant. (C) TET- and g-butyrolactone (SCB1)-regulated
TS-TA (pMX10)-mediated transactivation of the pMX9-encoded hybrid promoter enables programming of discrete SEAP expression levels in
response to a speciﬁc combination of inhibitory concentrations (1mg/ml) of TET and SCB1. HEK-293T cells were co-transfected with pMX10
(TS-TA) and pMX9 (PST-TA/TS-TA2) and cultivated in medium containing different combinations of trigger compounds. HEK-293T cells exclusively
transfected with pMX9 (PST-TA/TS-TA2) were used as control. Cells were grown for 48 h before SEAP levels were quantiﬁed in the culture supernatant.
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expected, owing to the twin tetO, PST-TA/TS-TA2 always
provided higher maximum expression levels when fully
induced (Figure 7B). Addition of TET partially reduced
SEAP levels to intermediate high-level expression, as TS-
TA’s ScbR component continues to bind and activate the
hybrid promoter (PST-TA/TS-TA2). Likewise, administration
of SCB1 reduces SEAP expression to intermediate low-
level expression as TS-TA’s TetR module remains bound
to the hybrid promoter. Only in the presence of both trigger
molecules, SEAP expression is shut down (Figure 7C).
Overall, SCB1 seems to be a more efﬁcient release trigger
for TS-TA than TET. Therefore, dual TetR-family
transactivators can be programmed by different trigger
molecules to provide distinct transcription activities from
hybrid promoters and mediate discrete transgene expres-
sion levels (Figure 7C). Interestingly, TS-TA, which failed
to address single promoters (Figure 2A), was fully oper-
ational in combination with hybrid promoters, suggesting
that tandem transactivators and hybrid promoters could be
matched for optimal regulation performance. These
ﬁndings suggest that natural tandem TetR-family tran-
scription factors may enable DPDT relay switch character-
istics with mutually exclusive graded expression proﬁles for
different sets of target genes driven by individual target
promoters while enabling discrete inducer programmed ex-
pression levels for hybrid promoter conﬁgurations.
DISCUSSION
Synthetic biology is an engineering-driven approach to
assemble modular biological parts in a rational and pre-
dictable manner to design devices, systems and organisms
with novel and useful functions (53). Here, we have
deﬁned a novel scaffolding architecture for serial
assembly of trigger-inducible DNA-binding proteins that
could program expression from individual or hybrid target
promoters in a small molecule-responsive manner.
Scaffold transcription factors or control proteins with
multiple DNA-binding domains seem to be an evolu-
tion-proven design found to control lipid import and
metabolism in bacteria [Mce3R; (50,51)] as well as differ-
entiation in mammalian cells [POU domain-containing
proteins such as Oct-1, Oct-2; (29)]. However, the func-
tionality and control dynamics of these bi-partite tran-
scription factors remain largely elusive. Intuitively,
bi-partite transcription factors can address two different
types of promoters or single promoters containing differ-
ent operator sites and so program expression of two dif-
ferent sets of genes or (co-)modulate transcription of a
single target gene in a speciﬁc manner. Indeed, synthetic
mammalian tandem transcription factors, assembled by
fusing up to three different prokaryotic DNA-binding
proteins of the TetR and GntR types to a single transac-
tivation domain, enabled trigger-controlled expression of
three different expression units. Permutation of individual
DNA-binding proteins within a daisy-chain transcription
factor modulated its regulation performance. Overall,
multi-partite transcription factors not only retain the in-
dividual DNA-binding capacities of their components but
also the responsiveness to their speciﬁc trigger molecules.
As individual repressors and target promoters provide in-
dependent transcription control in a simpler fashion,
multi-partite transcription-control proteins may not have
evolved to exclusively modulate multiple genes.
One additional characteristic of multi-partite transcrip-
tion factors was discovered when evaluating their per-
formance on hybrid promoters containing matching
operator sites. The daisy-chain transcription factors
could control hybrid target promoters with discrete
expression proﬁles; full expression in the absence of
trigger molecules when both TetR-moieties are bound,
intermediate high-level expression in the presence of one
inducer molecule when only one TetR component is
bound, intermediate low-level expression when the other
repressor domain remains bound in the presence of the
second trigger compound and repression in the presence
of both control molecules, which abolishes binding of the
entire bi-partite transcription factor to the hybrid
promoter. Similar discrete expression proﬁles have previ-
ously been exclusively achieved by synthetic cascades in
which three independent transcription-control systems
were serially linked (14,55).
A second feature that bi-partite transcription factors
exhibited when expressed at low levels and when address-
ing two separate promoters was the DPDT relay switch
characteristics. The genetic DPDT relay switch enabled
reversible and graded mutually exclusive expression
swapping between different transgenes, as the daisy-chain
transactivator ﬁrst binds with higher afﬁnity to one
promoter and gradually ﬂips over to the second
promoter, as increasing concentrations of the trigger
compound dose dependently release the bi-partite tran-
scription factor from the original promoter. Like their
electric counterparts, genetic DPDT relay switches may
enable organisms to gradually and reversibly switch
between two distinct metabolic networks using a single
pair of input molecules.
Overall, we suggest that multi-partite transcription
factors may have evolved to (i) independently ﬁne tune
expression of different sets of target genes, (ii) enable
discrete expression levels when programming hybrid pro-
moters containing multiple operators and (iii) provide
DPDT relay switching of independent metabolic circuits.
Owing to the high modularity, orthogonality and inter-
operability of DNA-binding proteins the multi-partite
transactivator architecture will provide a novel addition
to the synthetic biology toolbox and may help design
complex mammalian designer circuits with unprecedented
design, complexity and logic operation capabilities.
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